Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model

Abstract Efforts are underway for the development of an effective vaccine against Helicobacter pylori infection. We prepared recombinant full-length (568 aa) H. pylori recombinant urease B (rUreB) protein and tested it for immunogenicity and protection. BALB/c mice received either rUreB (40 µg) plus...

Full description

Saved in:
Bibliographic Details
Published in:FEMS immunology and medical microbiology 2010-11, Vol.60 (2), p.142-146
Main Authors: Bégué, Rodolfo E., Sadowska-Krowicka, Halina
Format: Article
Language:English
Subjects:
adjuvant
Adjuvants, Immunologic
Aluminum
Aluminum hydroxide
Aluminum Hydroxide - immunology
Animals
Antibodies, Bacterial - blood
Antigens
bacterial vaccine
Bacterial Vaccines - administration & dosage
Bacterial Vaccines - immunology
CpG islands
Disease Models, Animal
DNA - immunology
Freund's Adjuvant
Health risk assessment
Helicobacter Infections - immunology
Helicobacter Infections - prevention & control
Helicobacter pylori
Helicobacter pylori - immunology
Immunogenicity
Immunoglobulin A - blood
Immunoglobulin A - immunology
Immunoglobulin G - blood
Immunoglobulin G - immunology
Injections, Intramuscular
Injections, Subcutaneous
Mice
Mice, Inbred BALB C
mouse model
Oligodeoxyribonucleotides
Polymerase Chain Reaction
Recombinant Proteins - immunology
Repair & maintenance
Urease
Urease - immunology
urease B
Vaccines
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Efforts are underway for the development of an effective vaccine against Helicobacter pylori infection. We prepared recombinant full-length (568 aa) H. pylori recombinant urease B (rUreB) protein and tested it for immunogenicity and protection. BALB/c mice received either rUreB (40 µg) plus CpG (10 µg) intranasally, rUreB (50 µg) plus 3% aluminum hydroxide (50 µL) intramuscularly or rUreB (25 µg) plus Freund's adjuvant (25 µL) subcutaneously, three times (weeks 0, 2 and 6). Intranasal rUreB plus CpG was neither immunogenic nor protective; intramuscular rUreB plus aluminum hydroxide was immunogenic and modestly protective, and subcutaneous rUreB plus Freund's adjuvant was immunogenic and highly protective. The fact that protection was improved with Freund's adjuvant indicates that rUreB is a good antigen for a vaccine but that it needs a stronger adjuvant than aluminum hydroxide.
ISSN:0928-8244
1574-695X
2049-632X
DOI:10.1111/j.1574-695X.2010.00726.x